Maharashtra FDA Cancels Cipla Pune Warehouse Drug Licences

The Maharashtra FDA Cipla action cancels the drug sale and distribution licences of a Pune carrying-and-forwarding (C&FA) warehouse run by Cipla Pharma & Life Sciences Ltd, following fresh regulatory proceedings. The order, which covers Warehouse A at Wadki, Pune, was issued on 1 October 2026 and publicised on 2 October, according to reports by Free Press Journal and ETV Bharat. The regulator alleges misbranding of a Schedule H medicine and a series of storage and record-keeping lapses. Cipla has called the decision disappointing and says it is evaluating further options.

Key Takeaways

• The Maharashtra FDA cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd’s Wadki C&FA warehouse in Pune on 1 October 2026.
• The order was issued by the Assistant Commissioner (Drugs), Division 3, Pune, after fresh proceedings that followed Bombay High Court directions, according to ETV Bharat.
• The allegations include misbranding of the Schedule H tablet Reactin Plus and lapses in storage, documentation and inventory control.
• Cipla says it finds the decision disappointing, believes the warehouse complies with protocols, and is reviewing the order.
• These are regulatory allegations, not court findings. The effect on medicine supply was not specified in the reports we reviewed.

What Did the Maharashtra FDA Order Say?

The Maharashtra FDA order cancels the drug sale and distribution licences of the warehouse at Wadki, which Cipla uses to store and dispatch medicines. The order dated 1 October 2026 was issued after a revised show-cause notice, a written reply from the company and a personal hearing. FDA Commissioner Tukaram Mundhe is named in the coverage as the head of the regulator.

ETV Bharat reports that initial action against the facility began on 27 August 2026 on similar grounds, and that fresh proceedings followed directions from the Bombay High Court. The latest order concludes those fresh proceedings.

Maharashtra FDA Cipla Case at a Glance

What Are the Alleged Violations?

Misbranding of Reactin Plus

The regulator alleges that the packaging of Reactin Plus, a Schedule H medicine, carried unauthorised therapeutic claims. According to Punjab Kesari, the pack described the tablet as an analgesic for headache, muscular pain, backache, joint pain, sprain, body ache and toothache and included images suggesting pain relief. The FDA treated this as misbranding under the Drugs and Cosmetics Act, 1940. Schedule H drugs can be sold only on a prescription, so promotional claims on their packs are tightly controlled.

Storage and housekeeping lapses

• Medicines stored directly on the floor because of inadequate pallets or racks.
• Dust accumulation on stocks and inadequate cleanliness.
• No designated area for expired medicines marked Expiry – Not for Sale.

Records and documentation lapses

• The mandatory Form 35 inspection book was missing.
• No standard operating procedures or disposal records for expired medicines.
• Deficiencies in purchase and sales documentation.
• Discrepancies between the computerised SAP stock records and physical stock, including antibiotics, according to the Free Press Journal.

Timeline of the Proceedings

The sequence reported across the three outlets is: initial proceedings on 27 August; a revised show-cause notice on 4 September; Cipla’s written reply on 11 September; a personal hearing on 21 September; the cancellation order on 1 October; and public reporting on 2 October 2026.

What Cipla Said

Cipla said: “We find the Maharashtra FDA’s decision regarding our Wadki C&FA in Pune disappointing,” according to ETV Bharat. The company added that it maintains an unwavering commitment to quality and patient safety and is reviewing the order and evaluating further options. The Free Press Journal quotes the company as saying: “We believe our Pune C&FA warehouse operates in compliance with distribution and storage protocols and digital record-keeping standards.”

What It Means for Supply and the Industry

A C&FA warehouse is a distribution point between a manufacturer and its wholesalers and distributors, so losing licences at one site can affect how medicines move in that region. None of the reports we reviewed said whether supply of Cipla products had been disrupted or how the company would reroute stock. Cipla stresses it remains committed to uninterrupted access to safe medicines.

The case shows that Indian state regulators are scrutinising not only factories but also distribution warehouses, where storage conditions and records affect product quality. It follows other recent enforcement stories, including the Karnataka FDA counterfeit-medicine crackdown. Facility compliance also matters internationally, as in the US FDA review extension over facility issues for Novo Nordisk denecimig. For policy context, see our reports on the PRIP scheme for pharma and MedTech R&D and the talks on trade-margin rationalisation for medical devices.

What Happens Next

• Appeal or challenge: Cipla says it is reviewing the order and evaluating further options. No appeal had been reported at the time of writing.
• Supply arrangements: whether stock will be served from other Cipla sites has not been stated.
• Regulatory follow-up: any further action by the regulator or the central authority, the Central Drugs Standard Control Organisation (CDSCO), has not been reported.

Our Assessment

In our assessment, the Maharashtra FDA Cipla case is a significant regulatory action because licence cancellation is among the strongest measures available against a distribution site. The allegations are specific and mostly about housekeeping and documentation, but they remain allegations until tested on appeal, and Cipla disputes the findings. Readers should watch for the company response in court or before an appellate authority and for any statement on supply continuity.

Frequently Asked Questions

What did the Maharashtra FDA do to Cipla?

It cancelled the drug sale and distribution licences of the Cipla Pharma & Life Sciences C&FA warehouse at Wadki, Pune, by an order dated 1 October 2026.

Why were the licences cancelled?

The regulator alleges misbranding of Reactin Plus and lapses in storage, expired-drug handling, record-keeping and inventory control.

What is Cipla’s response?

Cipla finds the decision disappointing, believes the warehouse complies with protocols, and is reviewing the order and evaluating further options.

Does this affect all Cipla warehouses?

No. The order concerns the Wadki warehouse in Pune only, according to the reports we reviewed.

What is a C&FA warehouse?

A carrying-and-forwarding warehouse stores a manufacturer’s medicines and dispatches them to distributors and wholesalers.

How we reported this: information comes from reports by Free Press Journal, ETV Bharat and Punjab Kesari dated 2 October 2026. The allegations are those of the regulator as reported and are disputed by the company. We did not see the order itself. Last updated 3 October 2026. This article is for information only and is not legal or investment advice.